GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » XenoPort Inc (NAS:XNPT) » Definitions » E10

XenoPort (XenoPort) E10 : $-1.54 (As of Mar. 2016)


View and export this data going back to 2005. Start your Free Trial

What is XenoPort E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

XenoPort's adjusted earnings per share data for the three months ended in Mar. 2016 was $-0.230. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.54 for the trailing ten years ended in Mar. 2016.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-04-25), XenoPort's current stock price is $7.07. XenoPort's E10 for the quarter that ended in Mar. 2016 was $-1.54. XenoPort's Shiller PE Ratio of today is .


XenoPort E10 Historical Data

The historical data trend for XenoPort's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

XenoPort E10 Chart

XenoPort Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - -2.47 -1.61

XenoPort Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.81 -1.66 -1.62 -1.61 -1.54

Competitive Comparison of XenoPort's E10

For the Biotechnology subindustry, XenoPort's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


XenoPort's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, XenoPort's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where XenoPort's Shiller PE Ratio falls into.



XenoPort E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, XenoPort's adjusted earnings per share data for the three months ended in Mar. 2016 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2016 (Change)*Current CPI (Mar. 2016)
=-0.23/100.4704*100.4704
=-0.230

Current CPI (Mar. 2016) = 100.4704.

XenoPort Quarterly Data

per share eps CPI Adj_EPS
200606 -0.717 85.606 -0.842
200609 -0.670 85.606 -0.786
200612 -0.770 85.142 -0.909
200703 -0.136 86.640 -0.158
200706 0.520 87.906 0.594
200709 0.600 87.964 0.685
200712 0.080 88.616 0.091
200803 -0.290 90.090 -0.323
200806 -0.490 92.320 -0.533
200809 -0.960 92.307 -1.045
200812 -0.740 88.697 -0.838
200903 -0.100 89.744 -0.112
200906 -0.760 91.003 -0.839
200909 -0.810 91.120 -0.893
200912 -0.610 91.111 -0.673
201003 -0.930 91.821 -1.018
201006 -0.640 91.962 -0.699
201009 -0.650 92.162 -0.709
201012 -0.460 92.474 -0.500
201103 -0.490 94.283 -0.522
201106 0.550 95.235 0.580
201109 -0.530 95.727 -0.556
201112 -0.470 95.213 -0.496
201203 -0.260 96.783 -0.270
201206 -0.220 96.819 -0.228
201209 -0.410 97.633 -0.422
201212 0.120 96.871 0.124
201303 -0.500 98.209 -0.512
201306 -0.510 98.518 -0.520
201309 -0.390 98.790 -0.397
201312 -0.400 98.326 -0.409
201403 -0.360 99.695 -0.363
201406 -0.310 100.560 -0.310
201409 0.130 100.428 0.130
201412 -0.290 99.070 -0.294
201503 -0.330 99.621 -0.333
201506 -0.390 100.684 -0.389
201509 -0.380 100.392 -0.380
201512 -0.200 99.792 -0.201
201603 -0.230 100.470 -0.230

Add all the adjusted EPS together and divide 10 will get our e10.


XenoPort  (NAS:XNPT) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


XenoPort E10 Related Terms

Thank you for viewing the detailed overview of XenoPort's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


XenoPort (XenoPort) Business Description

Traded in Other Exchanges
N/A
Address
XenoPort Inc is a Delaware corporation was incorporated on May 19, 1999. The Company is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological and other disorders. Its product candidates are prodrugs that are created by modifying the chemical structure of currently marketed drugs, referred to as parent drugs, and are designed to correct limitations in the oral absorption, distribution and metabolism of the parent drug. Its marketed product is approved in the United States, where it is known as Horizant Extended-Release Tablets, and in Japan, where it is known as Regnite Extended-Release Tablets. Horizant has been approved by the U.S. Food and Drug Administration, or FDA, for the treatment of moderate-to-severe primary restless legs syndrome, or RLS, in adults and for the management of postherpetic neuralgia, or PHN, in adults. Restless legs syndrome, also known as Willis-Ekbom Disease, is a neurological disorder characterized by an urge to move the legs, usually caused or accompanied by uncomfortable and unpleasant sensations in the legs. PHN is a neuropathic pain syndrome that can follow the healing of an outbreak of herpes zoster, commonly known as shingles. Regnite has been approved by the Japanese Ministry of Health, Labor and Welfare, or MHLW, as a treatment for patients with moderate-to-severe RLS. It is also engaged with third parties for the development of arbaclofen placarbil, or AP, a potential treatment for spasticity in patients with spinal cord injury; and XP21279, a potential treatment for patients with advanced idiopathic Parkinson's disease. The Company faces competition from manufacturers of generic drugs. The Company is subject to regulation by regional, national, state and local agencies, including the Department of Justice, the Federal Trade Commission, the Office of Inspector General of the U.S. Department of Health and Human Services and other regulatory bodies, as well as governmental authorities in those foreign countries in which it may commercialize its products.
Executives
William Jl Rieflin director NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Cathy Friedman director C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Wendall Wierenga director 12790 EL CAMINO REAL, C/O NEUROCRINE BIOSCIENCES, SAN DIEGO CA 92130
Dennis M Fenton director
William G Harris officer: See Remarks C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Jeryl L Hilleman director C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
John Gordon Freund director 125 UNIVERSITY AVE., C/O SKYLINE VENTURES, PALO ALTO CA 94301
Paul L Berns director 11080 CIRCLEPOINT RD., STE, 200, WESTMINSTER CO 80020
Deerfield International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Ronald W Barrett director, officer: Chief Executive Officer C/O XENOPORT, INC., 3410 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051

XenoPort (XenoPort) Headlines

From GuruFocus

XenoPort Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 11-09-2010

XenoPort Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 05-10-2010

XenoPort Inc. Reports Operating Results (10-Q)

By gurufocus 10qk 08-06-2010

Xenoport - A Shaking Ham Hock

By Scott Waxler Wax 02-07-2010